My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 436

    1.

    Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor.

    Burcelin R, Da Costa A, Drucker D, Thorens B.

    Diabetes. 2001 Aug;50(8):1720-8.PMID: 11473030 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.

    Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA.

    Diabetologia. 2002 Oct;45(10):1410-5. Epub 2002 Sep 5. Erratum in: Diabetologia. 2003 Nov;46(11):1589. PMID: 12378382 [PubMed - indexed for MEDLINE]Related articles

    3.

    Portal glucose infusion in the mouse induces hypoglycemia: evidence that the hepatoportal glucose sensor stimulates glucose utilization.

    Burcelin R, Dolci W, Thorens B.

    Diabetes. 2000 Oct;49(10):1635-42.PMID: 11016446 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones.

    Ionut V, Hucking K, Liberty IF, Bergman RN.

    Diabetologia. 2005 May;48(5):967-75. Epub 2005 Apr 14.PMID: 15830188 [PubMed - indexed for MEDLINE]Related articles

    5.

    Blood glucose lowering and glucagonostatic effects of glucagon-like peptide I in insulin-deprived diabetic dogs.

    Freyse EJ, Becher T, El-Hag O, Knospe S, Göke B, Fischer U.

    Diabetes. 1997 May;46(5):824-8.PMID: 9133550 [PubMed - indexed for MEDLINE]Related articles

    6.

    Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region.

    Dardevet D, Moore MC, Neal D, DiCostanzo CA, Snead W, Cherrington AD.

    Am J Physiol Endocrinol Metab. 2004 Jul;287(1):E75-81. Epub 2004 Mar 16.PMID: 15026303 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.

    Gutniak MK, Juntti-Berggren L, Hellström PM, Guenifi A, Holst JJ, Efendic S.

    Diabetes Care. 1996 Aug;19(8):857-63.PMID: 8842604 [PubMed - indexed for MEDLINE]Related articles

    8.

    Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

    Toft-Nielsen MB, Madsbad S, Holst JJ.

    Diabetes Care. 1999 Jul;22(7):1137-43.PMID: 10388979 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.

    Parkes DG, Pittner R, Jodka C, Smith P, Young A.

    Metabolism. 2001 May;50(5):583-9.PMID: 11319721 [PubMed - indexed for MEDLINE]Related articles

    10.

    No effect of beta-adrenergic blockade on hypoglycaemic effect of glucagon-like peptide-1 (GLP-1) in normal subjects.

    Toft-Nielsen M, Hvidberg A, Hilsted J, Dige-Petersen H, Holst JJ.

    Diabet Med. 1996 Jun;13(6):544-8.PMID: 8799658 [PubMed - indexed for MEDLINE]Related articles

    11.

    Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.

    Sandhu H, Wiesenthal SR, MacDonald PE, McCall RH, Tchipashvili V, Rashid S, Satkunarajah M, Irwin DM, Shi ZQ, Brubaker PL, Wheeler MB, Vranic M, Efendic S, Giacca A.

    Diabetes. 1999 May;48(5):1045-53.PMID: 10331409 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs.

    Nishizawa M, Moore MC, Shiota M, Gustavson SM, Snead WL, Neal DW, Cherrington AD.

    Am J Physiol Endocrinol Metab. 2003 May;284(5):E1027-36. Epub 2003 Feb 4.PMID: 12569088 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Exenatide can reduce glucose independent of islet hormones or gastric emptying.

    Ionut V, Zheng D, Stefanovski D, Bergman RN.

    Am J Physiol Endocrinol Metab. 2008 Aug;295(2):E269-77. Epub 2008 May 20.PMID: 18492781 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.

    Kolligs F, Fehmann HC, Göke R, Göke B.

    Diabetes. 1995 Jan;44(1):16-9.PMID: 7813808 [PubMed - indexed for MEDLINE]Related articles

    15.

    Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.

    Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC.

    Diabetes. 1996 Nov;45(11):1524-30.PMID: 8866556 [PubMed - indexed for MEDLINE]Related articles

    16.

    Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats.

    Vahl TP, Tauchi M, Durler TS, Elfers EE, Fernandes TM, Bitner RD, Ellis KS, Woods SC, Seeley RJ, Herman JP, D'Alessio DA.

    Endocrinology. 2007 Oct;148(10):4965-73. Epub 2007 Jun 21.PMID: 17584962 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.

    Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W.

    Diabetes Care. 1998 Nov;21(11):1925-31.PMID: 9802745 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

    Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA.

    Diabetes Care. 1996 Jun;19(6):580-6.PMID: 8725855 [PubMed - indexed for MEDLINE]Related articles

    19.

    Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.

    Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA.

    Diabetes Care. 2003 Mar;26(3):791-8.PMID: 12610039 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice.

    Baggio L, Kieffer TJ, Drucker DJ.

    Endocrinology. 2000 Oct;141(10):3703-9.PMID: 11014225 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity